Compared to solid tumors, dysregulation of TP53 is less frequent in hematological malignancies, for example, in diffuse large B-cell lymphoma (DLBCL) and AML, ~10–50% of cases have alterations in TP53 (Figure 1). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.